Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Janssen Neuroscience R&D Newsroom

Janssen Neuroscience R&D Newsroom
Janssen Neuroscience R&D Newsroom

OUR Commitment to NEUROPSYCHIATRIC, NEURODEGENERATIVE AND NEUROLOGICAL CONDITIONS

 

Thank you for visiting the Janssen Neuroscience R&D Newsroom!

Below, please find our meeting news, social feeds, and more information about our progress and commitment to developing innovative medicines for neuropsychiatric, neurodegenerative, and neurological conditions, including depression, multiple sclerosis, Alzheimer's and more.

OUR Leadership

 

 

Bill Martin, Ph.D.
Global Therapeutic Area Head
Neuroscience
View Bill's Profile
 

Cesar Rodriguez
Vice President
Neuroscience
Global Commercial Strategy Organization
View Cesar's Profile
 

Allitia DiBernardo, M.D.
Global Head of Medical Affairs
Neurology
View Allitia's Profile
 


About NEUROSCIENCE

 

The Janssen Research & Development Neuroscience team is focused on neurodegenerative disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease; neurological/neuromuscular diseases, such as myasthenia gravis and epilepsy; and neuropsychiatric disorders, such as major depressive disorder, bipolar disorder, schizophrenia, and autism. Despite several advancements in neuroscience over the past 60 years, unmet need persists for patients across a broad range of these kinds of disorders. However, there has been significant progress in understanding and treating these diseases, and at Janssen, we never stop pushing the boundaries of what is possible.

 

Janssen Neuroscience R&D PRESENCE AT MEDICAL MEETINGS

 

Latest NEUROSCIENCE R&D News

 

Follow @JanssenGlobal for more news and information!